Skip to main content

Table 9 Scenario analyses results

From: Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

  Glargine NPH Incremental
Mean (SD) CI (low–high) Mean (SD) CI (low–high) Mean CI (low–high)
Scenario 1: LEAD study baseline cohort
 QALY 7.822 (0.108) 7.816–7.829 7.599 (0.11) 7.592–7.606 0.224 0.214–0.233
 Combined costs 774,826 (45,795) 771,988–777,664 750,724 (48,371) 747,726–753,722 24,102 20,692–27,511
 ICER      107,791 88,809–128,559
Scenario 2: split between SHE1:SHE2 as 1:1
 QALY 7.83 (0.101) 7.823–7.836 7.561 (0.103) 7.554–7.567 0.269 0.26–0.278
 Combined costs 766,965 (46,814) 764,063–769,866 764,116 (46,878) 761,210–767,021 2848 − 644 to 6341
 ICER      10,583 − 2317 to 24,391
Scenario 3: efficacy adjusted for both treatment arms
 QALY 7.81 (0.107) 7.803–7.816 7.673 (0.104) 7.667–7.68 0.137 0.127–0.146
 Combined costs 772,351 (48,678) 769,334–775,368 737,801 (50,299) 734,683–740,918 34,550 30,814–38,285
 ICER      253,115 211,061–301,461
Scenario 4: using PROcam risk equations
 QALY 7.06 (0.101) 7.054–7.066 6.87 (0.095) 6.864–6.876 0.19 0.181–0.199
 Combined costs 674,151 (42,343) 671,527–676,776 658,559 (41,865) 655,964–661,153 15,592 12,621–18,563
 ICER      82,023 63,427–102,560
Scenario 5: using UKPDS 82 risk equations
 QALY 7.837 (0.12) 7.829–7.844 7.63 (0.113) 7.623–7.637 0.206 0.196–0.217
 Combined costs 686,804 (48,701) 683,785–689,823 670,520 (48,519) 667,512–673,527 16,284 12,703–19,865
 ICER      78,897 58,540–101,355
  1. Values are expressed as mean (standard deviation)
  2. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SHE1 severe hypoglycaemic event (not requiring medical assistance), SHE2 severe hypoglycaemic event (requiring medical assistance)